Breast Cancer Research and Treatment **45**: 271, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 45

Aakvaag A 229
Abdi-Dezfuli F 229
Acito L 205
Akçfl E 1
Amorim WC 39
Anderson E 121
Anderson TJ 99
Arredondo MA 39

Baltina D 251
Bame PD 193
Barcellos-Hoff MH 81
Bascioni R 205
Ben-Eliyahu 159
Bennett JA 169
Berge RK 229
Blamey RW 219
Blumenson LE 39
Bonadonna G 193
Bonetti A 241
Bonetti F 241
Boniface G 29
Bordenave RH 211
Budel V 109
Budnick RM 135
Bullorsky EO 211

Cameron DA 99
Cavalcanti TCS 109
Cerrato A 141
Cetto GL 241
Chasseing NA 211
Cheung KL 219
Clarke RB 121
Corgnati A 241
Couture J 29

Damani M 29
Darro F 109
De Signoribus G 205
Decaestecker C 109
Demicheli R 193
Dessureault S 29
Diaz NB 211
Durham JR 55

Ellis IO 219
Ellmén J 251
Elston CW 219
Enriqueta M 135

Ferreira-Filho AF 39
Fortin A 63
Frierson HF Jr 55
Frisell J 263
Frittitta 141
Frøyland L 229

Gallinger S 29
Gariépy G 63
Garin A 251
Gasperin P 109
Gershanovich M 251
Giorgi F 205
Giuliodori L 205
Giustini L 205
Goldfine ID 141
Guimaraes RC 39

Hakama M 225
Hanigan MH 55
Hatschbach S 109
Hellström L 263
Herbert RA 149
Herman S 39
Hioki K 15
Holli K 225
Howell A 121

Ichise M 29
Isola J 225

Jacobson HI 169

Kamby C 181
Kangas L 251
Kara S 1
Kasunic TC 75
Kavas GÖ 1
Kirsh J 29
Kiss R 109
Kiyozuka Y 15
Klippenstein DL 39
Kocatürk PA 1
Köksoy C 1
Koven I 29
Kurebayashi J 15
Kurvet A 251

Langdon S 99
LaRue H 63
Lidbrink 263

Manfrin E 241
McEwan AJB 29
Micciolo R 241
Miller WR 99
Modena S 241
Molino A 241
Morici AC 39
Morimoto J 15
Murad AM 39
Murgita RA 169

Nambu H 15
Nava R 135
Ney E 149
Nicholson RI 219
Nortilli R 241
Norum J 7

Olsen JA 7
Özarslan 1

Page GG 159
Pétein M 109
Pinder SE 219
Piubello Q 241
Pollini GP 241

Rao GN 149
Recaldin E 241
Reddy KB 75
Reilly RM 29
Reiss M 81
Retsky M 193
Ritchie AA 99
Robertson JFR 219
Rumi LS 211
Rutqvist L-E 263

Saaristo R 225
Sacco MG 141
Salmon I 109
Sarkar FH 75
Schmocker B 29
Schwartsmann G 39
Semeniuk DJ 169
Sengeløv L 181
Shikata N 15
Sidlofsky S 29
Silva RR 205
Singh Y 15
Spagnolli P 241
Speer JF 193
Sperotto L 241
Stern H 29
Stewart CC 135
Stomper PC 39,135
Swartzendruber DE 193

Testa E 205
Têtu B 63
Thorsen T 229
Tomezzoli A 241
Trejo YG 211
Tsubura A 15
Turazza M 241

Valagussa P 193
Vigneri R 141
Visscher DW 75

Wang CS 63
Wardwell RH 193
Weidner N 141
Willsher PC 219
Winston JS 39
Wist EA 7

Breast Cancer Research and Treatment **45**: 273-276, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 45

adjuvant chemotherapy
computer simulation suggesting different benefits depending on size 193-202
alpha-fetoprotein
natural and recombinant human AFP identical as inhibitors of estrogen-dependent growth 169-179
amphiregulin
and heregulin in stromal cells predict recurrence 75-80
angiogenesis
MRI gadolinium enhancement associated with vessel density 39-46
angiogenesis inhibitors
TNP-470 inhibits growth and metastasis of breast cancer cell lines 15-27
antiestrogens
see tamoxifen, toremifene
apoptosis
induced by tamoxifen before fall in mitosis or tumor regression in ZR-75-1 cells 99-107
axillary imaging
immunoscintigraphy with Tru-Scint®AD™ 29-37

bone marrow fibroblast progenitors
reduced in breast cancer patients 211-218
breast conserving surgery
consistency of patient- and doctor-assessed cosmetic outcome 225-228
vs. mastectomy — cost-effectiveness 7-14

chemotherapy
phase II mitoxantrone/leucovorin/FU in anthracycline-pretreated patients 205-210
phase II trial of paclitaxel and ifosfamide in salvage 47-53
chromatin texture
by image cytometry, and hormone sensitivity in pregnancy-associated breast cancers 109-120
computer simulation
of relapse time distribution suggesting three metastatic growth phases 193-202
conservative treatment
see breast conserving surgery
copper
in red cells, decreased in breast cancer 1-6
cosmesis
patient- vs. doctor-assessed outcome of segmental mastectomy over time 225-228
cost-effectiveness
lumpectomy vs. mastectomy 7-14

diet
suppression of mammary tumors in c-*neu* transgenic mouse line by dietary fiber 149-158
drug resistance
mdr1 mRNA and P-glycoprotein levels vs. response to neoadjuvant chemotherapy or tamoxifen 63-74

eicosapentaenoic acid
inhibition of MCF-7 cell growth 229-239
endocrine therapy
phase III equivalence of toremifene 60mg/d and tamoxifen 40mg/d 251-262
second-line response predicted by ER and tumor grade 219-224
epidermal growth factor receptor (EGFR)
no association with amphiregulin or heregulin in tumor cells 75-80
estrogen receptor
comparison of immunohistochemical and biochemical methods for prognosis 241-249
prediction of response to second-line endocrine therapy 219-224
estrogen responses
PgR induction requires less E_2 than proliferation in normal breast tissue xenografts 121-133
estrogen-dependent growth
natural and recombinant human AFP identical as inhibitors 169-179
estrus cycle
NK suppression in rat proestrus/estrus and increased surgery-induced metastasis 159-167

fatty acids
inhibition of MCF-7 cell growth by analogs (including ω-3 and 3-thia) 229-239
fiber, dietary
suppression of mammary tumors in c-*neu* transgenic mouse line by diet 149-158
fibroblast progenitors
reduced in marrow of breast cancer patients 211-218
fine needle aspirates
flow cytometry of specimen mammography-guided FNA of dense vs. fatty benign breast tissue 135-139
mdr1 mRNA (RT-PCR) and P-glycoprotein levels vs. response to neoadjuvant chemotherapy or tamoxifen 63-74
flow cytometry
of specimen mammography-guided FNA of dense vs. fatty benign breast tissue 135-139
fluorouracil
phase II trial with mitoxantrone/leucovorin in anthracycline-pretreated patients 205-210
folinic acid
see leucovorin

gamma-glutamyl transpeptidase
loss in some *in situ* and infiltrating breast tumors 55-62
glutathione
loss of gamma-glutamyl transpeptidase in some *in situ* and infiltrating breast tumors 55-62
growth
inhibition by angiogenesis inhibitor TNP-470 15-27
growth model
computer simulation suggesting 3 metastatic growth phases 193-202

heregulin
and amphiregulin in stromal cells predict recurrence 75-80
hormone sensitivity
and chromatin texture by image cytometry in pregnancy-associated breast cancers 109-120

ifosfamide
and paclitaxel in Phase II trial of salvage therapy 47-53
image cytometry
chromatin pattern and hormone sensitivity in pregnancy-associated breast cancers 109-120
imaging
axillary nodal status using immunoscintigraphy with Tru-Scint®AD™ 29-37
MRI gadolinium enhancement associated with blood vessel density 39-46
immunohistochemistry
comparison of immunohistochemical and biochemical ER methods for prognosis 241-249
loss of gamma-glutamyl transpeptidase in some *in situ* and infiltrating breast tumors 55-62
stromal amphiregulin and heregulin predict recurrence 75-70
insulin receptor
increased in breast cancers induced by three different oncogenes in transgenic mice 141-147
interleukin-1β
reduced in marrow fibroblast cultures of breast cancer patients 211-218

leucovorin
phase II trial with mitoxantrone/FU in anthracycline-pretreated patients 205-210
locoregional recurrence
prognostic factors for survival after recurrence 181-192
lumpectomy
vs. mastectomy — cost-effectiveness 7-14

magnesium
in plasma and red cells, unchanged in breast cancer 1-6
magnetic resonance imaging (MRI)
gadolinium enhancement associated with vessel density 39-46
mammography
age dependence of mortality reduction in Stockholm screening trial 263-270
guidance for FNA of dense vs. fatty benign breast tissue 135-139
mastectomy
vs. lumpectomy — cost-effectiveness 7-14

MCF-7 cells
fatty acid analogs (including ω-3 and 3-thia) and growth inhibition 229-239
MDA-MB-231 cells
no effect of tamoxifen on apoptosis, mitosis, or tumor growth 99-107
mdr1 mRNA
and P-glycoprotein levels vs. response to neoadjuvant chemotherapy or tamoxifen 63-74
menstrual cycle
NK cell suppression in rat proestrus/estrus and increased surgery-induced metastasis 159-167
metastasis
computer model suggesting three metastatic growth phases 193-202
increased by surgery, especially in proestrus/estrus with reduced NK cell activity 159-167
inhibition by angiogenesis inhibitor TNP-470 15-27
mitosis
decreased by tamoxifen after induced apoptosis in ZR-75-1 cells 99-107
mitoxantrone
phase II trial with leucovorin/FU in anthracycline-pretreated patients 205-210
multidrug resistance
mdr1 mRNA and P-glycoprotein levels vs. response to neoadjuvant chemotherapy or tamoxifen 63-74

natural killer cells
suppression in proestrus/estrus and increased surgery-induced metastasis 159-167
necrosis
decreased by tamoxifen after ZR-75-1 tumor regression 99-107
neoadjuvant chemotherapy
mdr1 mRNA and P-glycoprotein levels vs. response 63-74
neu transgenic mice
development of mammary tumors suppressed by dietary fiber 149-158
nodal status
immunoscintigraphy with Tru-Scint®AD™ 29-37
normal breast tissue
dense vs. fatty – flow cytometry of specimen mammography-guided fine needle aspirates 135-139
PgR induction requires less E_2 than proliferation in xenografts 121-133

oncogenes
relationship with insulin receptor 141-147

P-glycoprotein
and *mdr1* mRNA levels vs. response to neoadjuvant chemotherapy or tamoxifen 63-74
paclitaxel
and ifosfamide in Phase II trial of salvage therapy 47-53
paracrine growth factors
stromal amphiregulin and heregulin predict recurrence 75-70
pregnancy-associated breast cancers
hormone sensitivity association with chromatin pattern by image cytometry 109-120
prevention model
development of mammary tumors in c-*neu* transgenic mouse line is diet-dependent 149-158
progesterone receptor
requires less estradiol than proliferation in normal breast tissue xenografts 121-133
prognostic factors
estrogen receptor — comparison of immunohistochemical and biochemical methods 241-249
for survival after locoregional recurrence 181-192
LDH and number positive nodes, for survival after locoregional recurrence 181-192
proliferation
requires more estradiol than PgR induction in normal breast tissue xenografts 121-133
prostaglandin-E2
increased in marrow mononuclear cells of breast cancer patients 211-218

quality of life
lumpectomy vs. mastectomy — cost-effectiveness 7-14

relapse time distribution
computer model suggesting three metastatic growth phases 193-202
risk assessment
flow cytometry of specimen mammography-guided FNA of dense vs. fatty benign breast tissue 135-139

salvage therapy
Phase II trial of paclitaxel and ifosfamide 47-53
screening mammography
age dependence of mortality reduction in Stockholm trial 263-270
superoxide dismutase
in red cells, increased in breast cancer 1-6
surgery
lumpectomy vs. mastectomy 7-14
surgery, menstrual cycle dependence
NK cell suppression in rat proestrus/estrus and increased surgery-induced metastasis 159-167

tamoxifen
40mg/d, equivalent to toremifene 60mg/d in phase III 251-262
apoptosis induced before fall in mitosis or tumor regression in ZR-75-1 cells 99-107
mdr1 mRNA and P-glycoprotein levels vs. response 63-74
mediation by TGFβ — hypothesis on TGFβ actions 81-95
taxol
see paclitaxel
TNP-470
angiogenesis inhibitor, inhibits growth and metastasis of breast cancer cell lines 15-27
toremifene
60mg/d, equivalent to tamoxifen 40mg/d in phase III 251-262
trace elements
in benign and malignant breast disease 1-6
transforming growth factor β (TGFβ)
early inhibition and later promotion of breast cancer — hypothesis 81-95
transgenic mice
development of mammary tumors in c-*neu* transgenic line is diet-dependent 149-158
Tru-Scint®AD™
immunoscintigraphy for axillary imaging 29-37
tumor grade
prediction of response to second-line endocrine therapy 219-224

vessel density
MRI gadolinium enhancement associated with angiogenesis 39-46

zinc
in red cells, increased in breast cancer 1-6
ZR-75-1 cells
tamoxifen-induced apoptosis precedes fall in mitosis and regression 99-107